Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
In eight subjects with Parkinson's disease under an optimal daily dose of L-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the L-dopa-induced stimulus.
D000368:Aged; D001519:Behavior / Q000187:drug effects*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D010919:Placebos; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D010919:Placebos; D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone; D009075:MSH Release-Inhibiting Hormone